Dual-Gene CRISPR Editing via Peptide Dendrimers Regulates Redox Balance for Diabetic Wound Repair.
Peptide dendrimers just got a spotlight in gene editing, and the results are hard to ignore. Researchers at Nanjing Tech University and collaborators delivered a dual-gene CRISPR/Cas9 payload using peptide-modified lysine dendrimers, targeting two genes at once. The goal? Tackle redox imbalance—a major roadblock in diabetic wound healing.
Biomacromolecules
by Jiang Y, Wen H, Xu J et al.
“Dual-Gene CRISPR Editing via Peptide Dendrimers Regulates Redox Balance for Diabetic Wound Repair. Jiang Y(1)(2), Wen H(1), Xu J(1), Peng W(1)(3), Zhou J(4), Mao H(1), Gu Z(1), He Y(1)(5). Author information: (1)College of Materials Science and Engineering, Nanjing Tech University, Nanjing 211816, P.R. China. (2)Department of Chemistry and Biochemistry, Freie Universität Berlin, Takustraße 3, Berlin 14195, Germany. (3)School of Chemistry and Molecular Engineering, Nanjing Tech University, Nanjing 211816, P.R. China. (4)Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, P.R. China. (5)Sino-Spain Joint Laboratory on Biomedical Materials (S2LBM), Jiangsu Collaborative Innovation Center for Advanced Inorganic Function Composites, Nanjing Tech University, Nanjing 211816, P.R. China. The management of chronic diabetic wounds, plagued by persistent oxidative stress, remains a major clinical challenge. We devised a CRISPR/Cas9-based gene therapy to fundamentally reprogram this pathological microenvironment. A single system was engineered for the simultaneous knockdown of Keap1 and PHD2, key negative regulators of the Nrf2 and HIF-1α pathways, respectively. This payload was delivered by multifunctional peptide-modified lysine dendrimers (MsRNPs), which self-assembled into stable, positively charged nanoparticles that effectively complexed with DNA. The MsRNPs showed excellent biocompatibility and mediated efficient cellular uptake and gene editing in vitro, leading to reduced ROS levels. Consequently, a single topical application of the polyplexes in a diabetic mouse model robustly accelerated wound closure, enhanced collagen deposition, and promoted angiogenesis, driven by the synergistic activation of Nrf2 and HIF-1α. This study establishes a novel combinatorial gene-editing strategy and a versatile nanoplatform for treating oxidative stress-related pathologies.”
Here’s how it went down. The team engineered dendrimer nanoparticles to carry CRISPR machinery targeting Keap1 and PHD2, genes that block the Nrf2 and HIF-1α pathways. Both are big players in handling oxidative stress and promoting tissue repair. The peptide dendrimers formed stable, positively charged complexes with the gene-editing tools, making cellular uptake easy and efficient.
Key takeaway: these peptide-based carriers didn’t just get the CRISPR system into cells—they did it with solid biocompatibility. In diabetic mouse models, a single topical dose reduced reactive oxygen species (ROS) in the wound, sped up closure, boosted collagen buildup, and ramped up new blood vessel growth. Activation of both Nrf2 and HIF-1α pathways happened at once, showing clear synergy.
Why does this matter for peptide research?
Peptide dendrimers aren’t just for delivery—they actively enable precision gene editing
This approach could open new doors for managing any condition linked to oxidative stress, not just wounds
The nanoplatform is modular; swapping genes or pathways is on the table
If you’re keeping track of next-gen delivery systems, this is a case study worth bookmarking. For more on advances in peptide carriers and gene editing, check the peptide research index. Interested in sourcing or developing similar systems? Browse the vendor directory for potential collaborators.
Peptide-enabled gene editing is moving from theory to proof-of-concept fast. The research community is taking notes.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.